Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

$19.99

Common-Size Income Statement

Paying users area

The data is hidden behind: . Unhide it.

  • Get 1-month access to Bristol-Myers Squibb Co. for $19.99, or

  • get full access to the entire website for at least 3 months from $49.99.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Bristol-Myers Squibb Co., common-size consolidated income statement

Microsoft Excel LibreOffice Calc
12 months ended: Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Net product sales
Alliance and other revenues
Revenues
Cost of products sold, excludes amortization of acquired intangible assets
Gross margin
Marketing, selling and administrative
Research and development
IPRD charge, MyoKardia acquisition
Amortization of acquired intangible assets
Operating income (loss)
Interest expense
Royalties and licensing income
Equity investment gains (losses)
Integration expenses
Contingent consideration
Loss on debt redemption
Provision for restructuring
Litigation and other settlements
Transition and other service fees
Investment income
Pension and postretirement
Divestiture gains
Reversion excise tax
Intangible asset impairment
Acquisition expenses
Other
Other income (expense), net
Earnings (loss) before income taxes
Provision for income taxes
Net earnings (loss)
Noncontrolling interest
Net earnings (loss) attributable to BMS

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

Income statement item Description The company
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Bristol-Myers Squibb Co. operating income (loss) as a percentage of revenues decreased from 2019 to 2020 but then increased from 2020 to 2021 not reaching 2019 level.
Earnings (loss) before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Bristol-Myers Squibb Co. earnings (loss) before income taxes as a percentage of revenues decreased from 2019 to 2020 but then increased from 2020 to 2021 not reaching 2019 level.
Net earnings (loss) attributable to BMS The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Bristol-Myers Squibb Co. net earnings (loss) attributable to BMS as a percentage of revenues decreased from 2019 to 2020 but then increased from 2020 to 2021 exceeding 2019 level.